Introduction {#section1-1076029618778140}
============

Appropriate diagnosis of PL-Apo and distinguishing PL-Apo from PL-Act is an important issue of platelet physiology investigations. However, in diagnosing PL-Apo, there is a risk of *false-negative* or *false-positive PL-Apo diagnosis*.

Two difficulties complicate an appropriate PL-Apo diagnosis. First, anucleate platelets appear in the circulation as a result of fragmentation from megakaryocytes, a process that may involve apoptosis in platelet precursor cells megakaryocytes.^[@bibr1-1076029618778140][@bibr2-1076029618778140]--[@bibr3-1076029618778140]^ Second, exposure of phosphatidylserine (PS) on the platelet surface may be involved in 2 platelet reactions: PL-Act facilitating blood coagulation and PL-Apo facilitating platelet clearance from the circulation by phagocytosis (reviewed in Leytin and Gyulkhandanyan et al^[@bibr4-1076029618778140],[@bibr5-1076029618778140]^). The goal of the current article is, based on analysis of relevant publications, to present recommendations that may help to avoid incorrect PL-Apo diagnosis.

We will discuss the following questions relevant to diagnosis of PL-Apo in unknown experimental and clinical settings: (1) what platelet preparation should be used for minimizing artificial stimulation of PL-Apo during purification of platelets from red and white blood cells; (2) how to distinguish PL-Apo from PL-Act and what markers should be used for characterizing *molecular* and *cellular* manifestations of PL-Apo; (3) what optimal conditions should be determined for selective stimulation of PL-Apo with unknown triggers of PL-Apo for avoiding a *false-negative* or *false-positive PL-Apo diagnosis*; and (4) what positive and negative controls should be used for quantification of PL-Apo and PL-Act responses.

Platelet Isolation Procedure {#section2-1076029618778140}
============================

The platelet isolation procedure may potentially lead to a *false-positive* PL-Apo diagnosis. To minimize artificial apoptotic changes during platelet isolation, we recommend using platelet-rich plasma (PRP). Flow cytometric analysis of the PRP by staining platelet surface glycoproteins (GPs) with anti-GPIIbIIIa and anti-GPIbα antibodies indicates that approximately 99% cells are positive for both markers, demonstrating a high purity of the PRP preparation^[@bibr6-1076029618778140]^ with only 1% to 3% of apoptotic and activated platelets.^[@bibr7-1076029618778140]^ Further purification of PRP by gel filtration, however, results in cellular morphological manifestations of PL-Apo, induced by platelet isolation stress, such as platelet surface membrane blebbing, extrusion of long filopods, shedding of platelet microparticles, and platelet shrinkage.^[@bibr4-1076029618778140]^ Therefore, we advise using PRP rather than isolated platelets in studies of PL-Apo. This is particularly important when PL-Apo is stimulated with weak or moderate PL-Apo triggers.

Experimental and Clinically Relevant Cases of Selective or Concurrent Stimulation of PL-Apo and PL-Act {#section3-1076029618778140}
======================================================================================================

The cases described in [Figure 1](#fig1-1076029618778140){ref-type="fig"} indicate clinical and experimental conditions for diagnosing PL-Apo, distinguishing it from PL-Act. This figure demonstrates the considerable diversity of PL-Apo and PL-Act responses in the following 7 cases.

![Stimulation of platelet apoptosis (PL-Apo), platelet activation (PL-Act), and both platelet responses: illustrative experimental and clinically relevant cases. In the **cases 1 to 4**, platelets were treated in vitro with 4 chemical agents: proapoptotic BH3 mimetic ABT-737, platelet agonist thrombin, calcium ionophore A23187, and potassium ionophore valinomycin. Note that the effects of these agents on PL-Apo and PL-Act responses at optimal treatment conditions are fundamentally different. In the **case 1**, ABT-737 selectively induces *molecular* but not *cellular* PL-Apo responses and does not induce or only weakly induce PL-Act. In contrast, in the **case 2**, thrombin selectively induces PL-Act, moderately induces *molecular* manifestations of PL-Apo, but does not induce or only weakly induces *cellular* manifestations of PL-Apo. In the **case 3**, A23187 induces both *molecular* and *cellular* PL-Apo and concurrently induces PL-Act. In the **case 4**, valinomycin induces only 1 of PL-Apo manifestations (ΔΨm depolarization) but does not induce other PL-Apo responses. The **case 5** demonstrates that injection of active anti-GPIIb (MWReg30) antibody at optimal dose induces molecular manifestation of PL-Apo in a murine model of immune thrombocytopenia. The **case 6** shows that PL-Act rather than PL-Apo is selectively induced during the storage of platelets in blood banking conditions for 2 to 12 days, but both PL-Act and PL-Apo are concurrently induced during platelet storage for 13 to 16 days. The **case 7** describes an impact of shear stresses on PL-Apo and PL-Act in vitro. Note that physiologic shear stresses do not induce PL-Apo and PL-Act, whereas pathologic high shear stresses concurrently induce both platelet responses. Detailed reported manifestations of PL-Apo and PL-Act for the cases 1 to 7 are presented in the text.](10.1177_1076029618778140-fig1){#fig1-1076029618778140}

In cases 1 to 4, platelets were treated in vitro with chemical agents (proapoptotic BH3 mimetic ABT-737, platelet agonist thrombin, calcium ionophore A23187, and potassium ionophore valinomycin) and analyzed at different doses, time, and temperature conditions. Cases 5 to 7 are illustration of clinically relevant cases.

ABT-737-Treated Platelets (Case 1) {#section4-1076029618778140}
----------------------------------

Treatment of platelets with ABT-737 is strongly dose-, time-, and temperature-dependent. At optimal 30 μmol/L ABT-737 dose,^[@bibr8-1076029618778140]^ prolonged treatment for 90 minutes at 37^o^C, rather than at room temperature (RT), is required to achieve the maximal level of *molecular* manifestations of PL-Apo, including ΔΨm depolarization, caspases-9, -8, and -3 activation, Bax and Bak proteins expression, and PS exposure on the platelet surface. At these optimal conditions, PL-Apo is selectively induced in comparison to PL-Act, determined as CD62 (P-selectin) exposure. However, *cellular* apoptotic events (platelet shrinkage and microparticle formation) are not induced or only weakly induced by ABT-737.^[@bibr7-1076029618778140],[@bibr9-1076029618778140][@bibr10-1076029618778140][@bibr11-1076029618778140][@bibr12-1076029618778140]--[@bibr13-1076029618778140]^ Nonoptimal dose, incubation time, or temperature conditions lead to false-negative diagnosis of PL-Apo.^[@bibr7-1076029618778140],[@bibr9-1076029618778140]^

Thrombin-Treated Platelets (Case 2) {#section5-1076029618778140}
-----------------------------------

In contrast, in thrombin-treated platelets, PL-Act (CD62 exposure), are selectively induced, compared to PL-Apo, in a wide range of thrombin doses from 0.05 to 1 U/mL, and this selective induction of PL-Act is persistent for 15 to 90 minutes at either 37^o^C or RT.^[@bibr6-1076029618778140],[@bibr7-1076029618778140],[@bibr9-1076029618778140],[@bibr10-1076029618778140],[@bibr14-1076029618778140]^ However, a thrombin dose titration study up to a very high dose of 10 U/mL has demonstrated that the percentage of cells with depolarized ΔΨm, activated caspase-3, and exposed PS is progressively increased up to 30% to 40%, whereas CD62 exposure is reached to the maximal level of 87% to 93% at the lowest thrombin doses 0.05 to 0.10 U/mL when only 4% to 12% platelets undergo apoptosis.^[@bibr14-1076029618778140]^ Thrombin (1.0 U/mL) also induces proapoptotic Bax and Bak expression and activation^[@bibr6-1076029618778140],[@bibr15-1076029618778140]^ but does not induce or only weakly induces *molecular* and *cellular* manifestations of PL-Apo.^[@bibr10-1076029618778140]^ Hence, a wide range (0.05-10 U/mL) thrombin dose titration is required to avoid a false-negative conclusion about the absence of PL-Apo, which becomes prominent and actually positive at high (2.5-10 U/mL) thrombin doses.^[@bibr14-1076029618778140]^

A23187-Treated Platelets (Case 3) {#section6-1076029618778140}
---------------------------------

Optimal conditions for A23187-treated platelets are dose- dependent but time- and temperature-independent. At saturating A23187 dose of 10 μmol/L,^[@bibr10-1076029618778140]^ and incubation for 15 to 90 minutes at 37^o^C or RT both *molecular* (ΔΨm depolarization, caspases-9, -8 and -3 activation, Bax and Bak expression and PS exposure) and *cellular* (platelet shrinkage and microparticle formation) manifestations of PL-Apo are induced concurrently with the induction of PL-Act, determined as CD62 exposure.^[@bibr7-1076029618778140],[@bibr9-1076029618778140][@bibr10-1076029618778140][@bibr11-1076029618778140][@bibr12-1076029618778140]--[@bibr13-1076029618778140]^ An A23187 dose titration study performed in a wide range of doses (0.125-10.0 μmol/L) was required for avoiding a false-negative PL-Apo diagnosis at nonoptimal lower doses of 0.125 to 1.0 μmol/L when only 2% to 9% cells are apoptotic.^[@bibr10-1076029618778140]^

Valinomycin-Treated Platelets (Case 4) {#section7-1076029618778140}
--------------------------------------

Case 4 is a notable example when the treatment of platelets with potassium ionophore valinomycin at optimal dose of 1 μmol/L induces strong ΔΨm depolarization in almost all cells after short-term 15-minute incubation of platelets at RT, whereas other *molecular* and *cellular* manifestations of apoptosis are not stimulated. Thus, valinomycin performs targeted triggering of ΔΨm depolarization not associated with PL-Apo, indicating that ΔΨm depolarization may be not causal for PL-Apo.^[@bibr13-1076029618778140],[@bibr16-1076029618778140]^ An important lesson from this case is that diagnosis of PL-Apo in novel tested cases should not be based on the determination of a single apoptotic maker only, and other apoptotic markers should be analyzed in order to avoid a false-positive PL-Apo diagnosis.

Role of GPIIbIIIa in Execution of PL-Apo (Case 5) {#section8-1076029618778140}
-------------------------------------------------

Case 5 illustrates the role of platelet surface receptor glycoprotein IIbIIIa (GPIIbIIIa) in PL-Apo. Injection of active agonistic anti-GPIIb antibody (MWReg30) significantly induces *molecular* manifestations of PL-Apo (ΔΨm depolarization, caspase-3 activation, and PS exposure) in comparison to control non-immune immunoglobulin G in a murine model of immune thrombocytopenia, indicating that direct GPIIbIIIa-mediated signaling is able to induce PL-Apo.^[@bibr17-1076029618778140]^ However, using low doses of active MWReg30 antibody or nonactive anti-GPIIb antibodies, which are not able to trigger PL-Apo, may result in false-negative PL-Apo diagnosis.

Platelet Storage under Blood Banking Conditions (Case 6) {#section9-1076029618778140}
--------------------------------------------------------

Platelet storage lesion is a serious problem limiting the clinical use of platelet concentrates (PCs).^[@bibr18-1076029618778140]^ Case 6 elucidates the contribution of PL-Act and PL-Apo to the platelet storage lesion in PCs stored at 22^o^C under blood banking conditions. PL-Act (CD62 exposure) is selectively induced in comparison to PL-Apo in prestorage-leukoreduced PCs prepared by PRP method during conventional (2-5 days), extended (6-8 days), and long-term (11-12 days) storage of PCs with the mean percentage of CD62-positive cells 38.6%, 66.5%, and 92.0%, respectively. In contrast, PL-Apo markers (ΔΨm depolarization, caspase-3 activation, PS exposure, and microparticle formation) are not induced or only slightly (5%-11%) induced during platelet storage for 2 to 12 days. However, a long-term storage for 13 to 16 days results in concurrent stimulation of PL-Act and PL-Apo.^[@bibr19-1076029618778140]^ These data indicate that during platelet storage, PL-Act is triggered much earlier and stronger than PL-Apo, and PL-Act rather than PL-Apo mostly contributes to the platelet storage lesion during conventional and extended storage of PCs. Notably, if storage of PCs is limited to 12 days without subsequent storage for 13 to 16 days, it may lead to erroneous PL-Apo diagnosis and only determination of PL-Apo and PL-Act markers for all storage days helps to avoid false-negative and false-positive PL-Apo diagnosis.

Platelets Exposed to Shear Stresses (Case 7) {#section10-1076029618778140}
--------------------------------------------

Case 7 describes the study in which human PRP was exposed to shear stresses for 90 seconds at 37^o^C generated by cone-and-plate device.^[@bibr20-1076029618778140]^ Platelets subjected to physiologic levels of shear stresses occurring in arteries and arterioles (10-44 dyn/cm^2^) and pathologic high levels characteristic for stenotic vessels (117-388 dyn/cm^2^) have been examined for *molecular* (ΔΨm depolarization, caspase-3 activation, and PS exposure) and *cellular* (platelet shrinkage and microparticle formation) PL-Apo responses and for PL-Act responses (CD62 exposure and GPIbα downregulation).^[@bibr20-1076029618778140]^ The data demonstrate that physiologic shear stresses do not induce PL-Apo and PL-Act compared to control (0 dyn/cm^2^); in contrast, pathologic shear stresses concurrently stimulate both PL-Apo and PL-Act. These data indicate that not only chemical agents, such as A23187, but also mechanical rheological forces (pathologic high shear stresses) are able to induce both *molecular* and *cellular* manifestations of PL-Apo and PL-Act. It is important, however, to perform the study in a wide range of shear stresses. Otherwise, there is a risk of false-negative and false-positive PL-Apo diagnosis in inappropriate shear stress conditions.

Conclusions {#section11-1076029618778140}
===========

In summary, we recommend the following procedures for avoiding *false-negative* and *false-positive diagnoses* of PL-Apo in unknown experimental and clinical settings.

\(1\) Platelet-rich plasma, rather than isolated platelets, should be used to minimize artificial enhancement of PL-Apo induced by platelet isolation stress, which may result in a *false-positive PL-Apo diagnosis*.

\(2\) Since different doses, times, temperatures, and shear stresses are required for obtaining the maximal levels of PL-Apo and/or PL-Act induced by different triggers, a thorough elaboration of optimal conditions for stimulation of PL-Apo and PL-Act, separately or concurrently, is required by performing dose, time, temperature, and shear stress titrations in wide titration ranges. Detection of PL-Apo in nonoptimized conditions may lead to a *false-negative PL-Apo diagnosis*.

\(3\) Diagnosis of PL-Apo *should not* be based on the determination of a single apoptotic marker. As shown in case 4, detection of very strong ΔΨm depolarization in valinomycin-treated platelets, when almost all cells have depolarized mitochondrial inner membrane, does not ensure the execution of PL-Apo and only simultaneous determination of other molecular and cellular manifestations of PL-Apo prevents a *false-positive PL-Apo diagnosis*. These markers should be aimed at characterizing: (a) *molecular apoptotic events* (expression of proapoptotic Bax and Bak and antiapoptotic Bcl-xL and Bcl-2 proteins, permeabilization of mitochondrial inner and outer membranes, release of proapoptotic proteins (such cytochrome *c*) from mitochondria to the cytosol, activation of initiator and executioner caspases-9, -8, -3 and PS exposure, (b) *cellular apoptotic events* (platelet shrinkage and microparticle formation), and (c) *PL-Act events* (CD62 exposure, GPIIbIIIa upregulation, and GPIbα downregulation).

\(4\) Finally, A23187-treated and diluent buffer-treated platelets, and appropriate case-specific positive and negative controls should be used for quantification of PL-Apo and PL-Act responses.
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